Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 8.18% | 21.10% | 538.70% | 838.09% | 865.96% |
| Total Depreciation and Amortization | 17.50% | 9.34% | 5.20% | -1.87% | -15.63% |
| Total Amortization of Deferred Charges | 23.81% | 23.81% | 23.81% | 23.81% | 113.56% |
| Total Other Non-Cash Items | -32.70% | -58.89% | -48.42% | 90.39% | 209.86% |
| Change in Net Operating Assets | -18.13% | 16.81% | 24.84% | -132.93% | -2.27% |
| Cash from Operations | -0.63% | 11.61% | 532.58% | 837.19% | 541.25% |
| Capital Expenditure | -29.28% | -43.29% | -96.41% | -46.99% | -44.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 344.80% | 71.69% | 44.26% | 85.38% | 69.24% |
| Cash from Investing | -364.20% | 48.38% | 21.78% | 74.92% | 61.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.69% | 79.10% | 93.14% | 95.83% | 97.07% |
| Issuance of Common Stock | 40.37% | 25.90% | 20.63% | 11.43% | -14.76% |
| Repurchase of Common Stock | 48.68% | -22.05% | -17.87% | -50.89% | -104.76% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,240.00% | -128.57% | -109.09% | -104.84% | -113.16% |
| Cash from Financing | 226.36% | -21.50% | -16.61% | -51.27% | -110.51% |
| Foreign Exchange rate Adjustments | -214.60% | -164.56% | 474.29% | 313.38% | 13.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.59% | 199.77% | 118.28% | 108.89% | 94.88% |